Clinical Trials Browser

Phase 1/2 × Lisaftoclax × 90 days × Clear all

NCT07398638 2026-02-10

Lisatoclax Plus R-CHOP or Pola-R-CHP in Untreated DLBCL: A Phase Ib/II Study

Phase 1/2 Not yet recruiting

Lymphoma, Large B-Cell, Diffuse